Julio Gutierrez, MD

Articles

The Future of HCC Treatment

August 9th 2023

The panel closes their discussion by highlighting exciting developments on the horizon for the treatment of HCC.

Safety Profiles of Available Therapies in Advanced HCC

August 9th 2023

Dr Ghassan K. Abou-Alfa explains the safety profiles of the discussed frontline therapy options for advanced HCC.

Optimal Sequencing in Patients With Advanced HCC

August 3rd 2023

Key opinion leaders discuss the sequencing of systemic therapy options for patients with advanced HCC.

Updates in First-Line Systemic Therapy for Advanced HCC: The HIMALAYA Study

August 3rd 2023

Dr Manish Shah reviews data from the HIMALAYA study on front-line systemic therapy in advanced HCC with tremelimumab plus durvalumab.

Updates in First-Line Systemic Therapy for Advanced HCC: The IMbrave150 Trial

July 28th 2023

Julio Gutierrez, MD, and Ghassan K. Abou-Alfa, MD, discuss the results of the IMbrave150 study investigating atezolizumab plus bevacizumab in the first-line setting for advanced HCC.

The Role of Adjuvant Therapy in Patients With Early-Stage HCC

July 28th 2023

Experts review data from IMbrave050 on the potential role of atezolizumab plus bevacizumab in the adjuvant setting for HCC.

Treatment Approaches for Patients With Early-Stage HCC

July 19th 2023

Manish Shah, MD, details the role of locoregional therapy in HCC, and Julio Gutierrez, MD, comments on transplant as a curative option.

Factoring Stage and Hepatic Function Into Treatment Decision-Making for HCC

July 19th 2023

The panel explains the Child-Pugh scoring system and how staging and liver function impact treatment decisions for patients with HCC.

Diagnosing Patients With Hepatocellular Carcinoma

July 12th 2023

Key opinion leaders review the process of diagnosing HCC, the role of molecular testing, and associated challenges.

Overview of Hepatocellular Carcinoma (HCC)

July 12th 2023

Experts provide an overview of hepatocellular carcinoma, including the risk factors and prognosis.